Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.09 | 0.364520048603 | 24.69 | 25.32 | 20.68 | 161498 | 22.55254157 | CS |
4 | 5.25 | 26.8817204301 | 19.53 | 26.34 | 18.62 | 174963 | 23.24115161 | CS |
12 | 1.28 | 5.44680851064 | 23.5 | 26.34 | 18.62 | 252150 | 22.4139156 | CS |
26 | 1.28 | 5.44680851064 | 23.5 | 26.34 | 18.62 | 252150 | 22.4139156 | CS |
52 | 1.28 | 5.44680851064 | 23.5 | 26.34 | 18.62 | 252150 | 22.4139156 | CS |
156 | 1.28 | 5.44680851064 | 23.5 | 26.34 | 18.62 | 252150 | 22.4139156 | CS |
260 | 1.28 | 5.44680851064 | 23.5 | 26.34 | 18.62 | 252150 | 22.4139156 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.